Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | ZUMA-5: Axi-cel for R/R non-Hodgkin lymphoma

Caron Jacobson • 28 May 2020
EHA 2020
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T
ZUMA-5

Caron Jacobson, MD, MMSc, of the Dana-Farber Cancer Institute, Boston, MA, discusses the results from ZUMA-5 (NCT03105336), a pivotal, Phase II study investigating the use of axicabtagene ciloleucel in relapsed/refractory follicular lymphoma and marginal cell lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Caron Jacobson

Improving access and delivery of CAR T-cells and bispecific antibodies in the community 6:48
Improving access and delivery of CAR T-cells and bispecific antibodies in the community
Caron Jacobson et al. • 12 Apr 2025
Evolving frontline treatment in MCL: disease biology, the changing role of SCT & novel agents
Caron Jacobson et al. • 9 Oct 2024
Rapid CAR manufacture
Caron Jacobson et al. • 12 May 2023
Advances in CAR-T therapy for lymphoma 10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022

Related Videos

Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL 1:14
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam • 8 Dec 2025
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL 3:07
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Lorenzo Falchi • 6 Dec 2025
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL 3:05
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL
Adam Olszewski • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals